Acetohydroxamic Acid: Acetohydroxamic acid administered according to the protocol-defined dose and schedule, in combination with a short-course anti-tuberculosis regimen.
Placebo: Matching placebo identical in appearance, packaging, and administration schedule to acetohydroxamic acid, administered with the same short-course anti-tuberculosis regimen.
Study summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug-resistant tuberculosis (MDR-TB).
The primary objectives are to assess the safety and tolerability of AHA combined with short-course regimens, and to determine the recommended phase II dose (RP2D) of AHA.
The secondary objectives include evaluating the 8-week sputum culture conversion rate, pharmacokinetic parameters, and exploring DNA damage repair biomarkers as potential indicators of treatment response.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Age 14 to \< 65 years, male or female
* Confirmed rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB) by molecular testing (e.g., Xpert MTB/RIF) or drug susceptibility testing
* Positive sputum culture for Mycobacterium tuberculosis or positive molecular test
* Chest imaging consistent with active pulmonary TB, or histologically confirmed extrapulmonary TB (excluding CNS, osteoarticular, and disseminated TB)
* Body weight ≥ 40 kg
* Karnofsky Performance Status ≥ 50
* Adequate laboratory parameters:
* Hemoglobin ≥ 8.0 g/dL
* ANC ≥ 1000/mm³
* Platelets ≥ 75,000/mm³
* ALT/AST ≤ 3 × ULN
* Total bilirubin ≤ 2 × ULN
* Creatinine clearance ≥ 30 mL/min
* QTcF interval \< 450 ms (male) or \< 470 ms (female)
* HIV-negative, confirmed by approved testing
* No prior exposure to bedaquiline, delamanid, or linezolid for more than 1 month
* Female participants of childbearing potential must agree to use effective contraception and have a negative pregnancy test
* Signed informed consent
Exclusion Criteria:
* Central nervous system TB (e.g., TB meningitis), osteoarticular TB, or disseminated/miliary TB
* Known allergy or serious adverse reaction to any study drug or background regimen component
* Known resistance to bedaquiline, delamanid, or linezolid
* Use of anti-TB drugs within the past 30 days that may interfere with study assessments, except in documented treatment failure cases
* Severe comorbidities, including:
* NYHA Class III-IV heart failure
* History or risk factors for Torsades de Pointes
* Child-Pugh B or C cirrhosis
* Uncontrolled diabetes (HbA1c \> 10%)
* Active malignancy
* Current use of QT-prolonging medications that cannot be substituted
* Current use of MAO inhibitors or serotonergic drugs
* BMI \< 17 kg/m² with severe malnutrition
* Grade 3-4 peripheral neuropathy at baseline
* Pregnant or breastfeeding women
* Any condition that, in the investigator's judgment, may interfere with study completion or data interpretation
Primary outcome measure(s)
Change in Mycobacterium tuberculosis sputum bacterial load — Baseline to Day 14 Change in quantitative Mycobacterium tuberculosis colony-forming units (CFU) in sputum, expressed as log10 CFU/mL/day, measured using standardized microbiological culture methods.
Trial sites (2)
Facility
City
Region
Status
Anhui Chest Hospital
Hefei
Anhui
Shanghai Pulmonary Hospital
Shanghai
Shanghai Municipality
More Shanghai Pulmonary Hospital, Shanghai, China trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.